{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:33:39Z","timestamp":1773448419436,"version":"3.50.1"},"reference-count":33,"publisher":"FapUNIFESP (SciELO)","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  Background: Cirrhosis is one of the final stages of chronic liver disease. Common causes of cirrhosis include alcoholism and viral hepatitis infections. Cirrhosis can progress from an asymptomatic, compensated phase to decompensation and the appearance of overt symptoms. There is no specific treatment for decompensated cirrhosis. The ANSWER trial positioned long-term albumin infusions as a potential treatment for patients with cirrhosis and uncomplicated ascites.  Objective: This study assesses the economic impact of albumin infusions following the ANSWER trial regimen in Brazilian patients with decompensated cirrhosis from the public and private healthcare systems perspectives.  Methods: The incremental cost per patient per year was calculated for standard medical treatment (SMT) plus long-term albumin infusions versus SMT alone. Costs of diuretics and albumin were obtained from Banco de Pre\u00e7os em Sa\u00fade and the Drug Market Regulation Chamber. Costs for complication and procedures were gathered from the published literature. Costs were transformed to 2021 Brazilian reals (BRL). Incidences of clinical complications and treatments were gathered from the ANSWER trial. Univariate sensitivity analysis was performed by increasing and decreasing all inputs by 20%.  Results: The cost per patient per year was 118,759 BRL and 189,675 BRL lower for patients treated with SMT and albumin (compared to SMT only) for the public and private healthcare systems, respectively. The additional cost of albumin was offset by reduced complications and treatments (149,526 BRL and 249,572 BRL, respectively). The univariate sensitivity analysis showed cost savings for both healthcare systems in all the scenarios assessed.  Conclusion: This economic analysis suggests that, if the ANSWER trial clinical outcomes translate into real-world effectiveness, addition of albumin infusions to SMT in patients with decompensated cirrhosis may lead to cost savings for the public and private healthcare systems in Brazil.<\/jats:p>","DOI":"10.1590\/s0004-2803.230302023-65","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T11:35:50Z","timestamp":1695641750000},"page":"356-363","source":"Crossref","is-referenced-by-count":6,"title":["ALBUMIN VERSUS STANDARD MEDICAL TREATMENT IN BRAZILIAN PUBLIC AND PRIVATE HEALTHCARE SYSTEMS"],"prefix":"10.1590","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3069-128X","authenticated-orcid":false,"given":"Carlos","family":"TERRA","sequence":"first","affiliation":[{"name":"Universidade do Estado do Rio de Janeiro,  Brasil; Casa de Sa\u00fade S\u00e3o Jos\u00e9,  Brasil; Hospital Federal da Lagoa,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3253-0148","authenticated-orcid":false,"given":"Elisabet","family":"VIAYNA","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research,  Espanha"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4477-5604","authenticated-orcid":false,"given":"Laura","family":"AYZIN","sequence":"additional","affiliation":[{"name":"International Market Access,  Espanha"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0808-8161","authenticated-orcid":false,"given":"Cristina","family":"FUSTER","sequence":"additional","affiliation":[{"name":"Scientific and Medical Affairs,  Espanha"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2933-3998","authenticated-orcid":false,"given":"Susana","family":"ACEITUNO","sequence":"additional","affiliation":[{"name":"Universitat Jaume I Parc Cientific Tecnologic i Empresarial Edificio Espaitec 2,  Espanha"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3250-4776","authenticated-orcid":false,"given":"Claudio","family":"TAFLA","sequence":"additional","affiliation":[{"name":"Nilo Sa\u00fade,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2023,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.6061\/clinics\/2013(03)OA02","article-title":"Etiology of liver cirrhosis in Brazil: chronic alcoholism and hepatitis viruses in liver cirrhosis diagnosed in the state of Espirito Santo","volume":"68","author":"Goncalves PL","year":"2013","journal-title":"Clinics"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"16041","DOI":"10.1038\/nrdp.2016.41","article-title":"Acute-on-chronic liver failure in cirrhosis","volume":"2","author":"Arroyo V","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"893","DOI":"10.5604\/01.3001.0010.5280","article-title":"Burden of Chronic Viral Hepatitis and Liver Cirrhosis in Brazil - the Brazilian Global Burden of Disease Study","volume":"16","author":"de Carvalho JR","year":"2017","journal-title":"Ann Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.21115\/JBES.v12.n2.p128-34","article-title":"Hospital expenses and liver disease in Brazil","volume":"12","author":"Hepp Schwambach K","year":"2020","journal-title":"Jornal Brasileiro de Economia da Sa\u00fade"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D\u2019Amico G","year":"2006","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/jhep.2003.50315","article-title":"The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club","volume":"38","author":"Moore KP","year":"2003","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Biggins SW","year":"2021","journal-title":"Hepatology"},{"key":"ref9","first-page":"301","article-title":"The role and indications of albumin in advanced liver disease","volume":"82","author":"Zaccherini G","year":"2019","journal-title":"Acta Gastroenterol Belg"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jhep.2022.03.005","article-title":"Long-term albumin treatment in patients with cirrhosis and ascites","volume":"76","author":"Caraceni P","year":"2022","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0168-8278(99)80194-9","article-title":"Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial","volume":"30","author":"Gentilini P","year":"1999","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3748\/wjg.v12.i9.1403","article-title":"Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial","volume":"12","author":"Romanelli RG","year":"2006","journal-title":"World J Gastroenterol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.13968","article-title":"Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites","volume":"39","author":"Di Pascoli M","year":"2019","journal-title":"Liver Int"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial","volume":"391","author":"Caraceni P","year":"2018","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jhep.2018.08.006","article-title":"Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial","volume":"69","author":"Sola E","year":"2018","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"100673","DOI":"10.1016\/j.aohep.2022.100673","article-title":"Economic evaluation of long-term albumin use in cirrhosis patients from the Mexican healthcare system perspective","volume":"27","author":"Moctezuma-Velazquez C","year":"2022","journal-title":"Ann Hepatol"},{"key":"ref17","series-title":"Annual cost of long-term treatment with human albumin in patients with cirrhosis and uncomplicated ascites","author":"Fernandez J","year":"2020"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"S615","DOI":"10.1016\/S0168-8278(22)01547-1","article-title":"Long term albumin administration is associated with reduced healthcare resource use in patients with uncomplicated cirrhotic ascites: results from a simulation model","volume":"77","author":"Bennett K","year":"2022","journal-title":"J Hepatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/S0140-6736(18)30948-6","article-title":"Long-term albumin in cirrhosis: is it the ANSWER?","volume":"391","author":"Garcia-Tsao G","year":"2018","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"100381","DOI":"10.1016\/j.aohep.2021.100381","article-title":"P-15 Waiting list for liver transplantations: Clinical and economic burden, retrospective study","volume":"24","author":"Rodriguez S","year":"2021","journal-title":"Ann Hepatol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"A122","DOI":"10.1016\/S1098-3015(10)67522-5","article-title":"Medical resource use and direct medical cost of chronic hepatitis C virus infection (HCV) in Brazil","volume":"6","author":"Fonseca MC","year":"2005","journal-title":"Value Health"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1590\/S1413-86702009000300007","article-title":"Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil","volume":"13","author":"Fonseca MC","year":"2009","journal-title":"Braz J Infect Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00019053-200826050-00006","article-title":"A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units","volume":"26","author":"Sogayar AM","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jhin.2020.07.015","article-title":"Costs of healthcare-associated infections to the Brazilian public Unified Health System in a tertiary-care teaching hospital: a matched case-control study","volume":"106","author":"Osme SF","year":"2020","journal-title":"J Hosp Infect"},{"key":"ref25","series-title":"Ag\u00eancia Nacional de Sa\u00fade Suplementar","year":"2022"},{"key":"ref26","first-page":"162","article-title":"Analysis of economic impact between the modality of renal replacement therapy","volume":"39","author":"Gouveia DSES","year":"2017","journal-title":"J Bras Nefrol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.transproceed.2014.05.017","article-title":"MELD score and albumin replacement are related to higher costs during management of patients with refractory ascites","volume":"46","author":"Borges de Santana V","year":"2014","journal-title":"Transplant Proc"},{"key":"ref28","series-title":"ANAHP Associacao Nacional de Hospitals Privados","year":"2022"},{"key":"ref29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007856","article-title":"Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis","volume":"13","author":"Brito NC","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"ref30","series-title":"Classifica\u00e7ao Brasileira Hierarquizada de Procedimentos M\u00e9dicos","year":"2022"},{"key":"ref31","series-title":"Banco de Pre\u00e7os em Sa\u00fade"},{"key":"ref32","series-title":"C\u00e2mara de Regula\u00e7\u00e3o do Mercado de Medicamentos","year":"2022"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","article-title":"The NICE Cost-Effectiveness Threshold","volume":"26","author":"McCabe C","year":"2008","journal-title":"Pharmacoeconomics"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":["An\u00e1lise de custos de pacientes cirr\u00f3ticos descompensados recebendo albumina a longo prazo versus tratamento m\u00e9dico padr\u00e3o nos sistemas de sa\u00fade p\u00fablico e privado do Brasil"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0004-28032023000300356&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T11:36:06Z","timestamp":1695641766000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032023000300356&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["S0004-28032023000300356"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.230302023-65","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}